31-Oct-23

InterCure Wins Cannolam Arbitration Proceeding

NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Compan y "), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release
17-Oct-23

InterCure Provides an Update Regarding the Security Situation in Israel

NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Compan y "), the leading medical cannabis company in Israel and outside of North America, today addressed the status of the security situation in the
31-Aug-23

InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY

Achieved record revenues of NIS 209 million ($ 7 5 million) 1 for the first half of 2023 Annualized revenue run rate of NIS 41 7 million ($ 149 million) Adjusted EBITDA 2 of NIS 30 million ($ 11 million) Generated NIS 35 million ($ 13 million) cash from operations in the second quarter Strong
10-Jul-23

InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE

NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(" InterCure " or the " Compan y "), announced today that its board of directors (“ Board ”) has approved the voluntarily delisting of the Company’s
09-Jun-23

InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(" InterCure " or the " Compan y "), reports today that, further to the Company’s press release issued on February 1, 2023, where the Company had
15-May-23

InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference

Mr. Rabinovitch is one of the global cannabis senior executives to participate NEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure") today announced that Alexander Rabinovitch, CEO of InterCure,
15-May-23

InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY

Achieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA (1) of $6 Million Strong balance sheet with over $45 million cash and Net current assets of over $72 million NEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE
15-May-23

InterCure to Be Featured with Mike Tyson in an Exclusive Interview on Fox Business

The Company will be featured on the Claman Countdown show on Monday to discuss its strong 2022 results and recent partnership with Mike Tyson NEW YORK and TORONTO and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: INCR ) (TSX: INCR.U) (TASE: INCR) ("InterCure'' or the "Company"), the
25-Apr-23

InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary

NEW YORK and TORONTO and HERZLIYA, Israel, April 25, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) (" InterCure " or the " Compan y "), the leading medical cannabis company outside of North America announces that on April 24, 2023, it was informed
20-Apr-23

InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries

Leading Global Pharmaceutical Cannabis Company, InterCure, signed an initial collaboration agreement with legendary boxer, entrepreneur and cannabis advocate Mike Tyson’s premium cannabis brand NEW YORK and TORONTO and HERZLIYA, Israel, April 20, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd .
Displaying 1 - 10 of 14